ClinicalTrials.gg
RecruitingNCT06443515ARTEUpdated Sep 24, 2024

Respiratory Trends During Blood Transfusions in Newborns.

An interventional study of lung ultrasound in Blood Transfusion Complication, Blood Transfusion Associated Adverse Reactions and Respiratory Complication, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged Up to 1 Month. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
Up to 1 Month
Sex
All
01

Study summary

The prevalence of transfusion reactions is between 1 and 11% of transfusions. Most reactions are mild and do not pose a life-threatening risk to the patient. More serious problems may be the only manifestations that lead to suspicion of a transfusion reaction.

Most noninfectious transfusion reactions are immune-mediated. Two main types of reactions can be distinguished: TACO (transfusion associated cardiac overload, which is a cardiogenic pulmonary edema) and TRALI (transfusion related acute lung injury, non-cardiogenic pulmonary edema).

Although TRALI are diagnoses of exclusion, the presence of noncardiogenic pulmonary edema and respiratory problems in the vicinity of blood product transfusions should raise suspicion. Other signs of TRALI are hypotension and tachycardia, while in TACO arterial hypertension with positive water balance can be observed.

According to previous reports, the prevalence of transfusion reactions in the neonatal population is approximately 8%. Factors associated with these reactions are low birth weight and low gestational age. However, diagnostic criteria of respiratory transfusion reactions are not uniform across studies, and often the generic terms "acute lung injury" have been used.

Therefore, the primary objective of this study is to evaluate the respiratory trend during blood transfusions; secondary objectives are the study of risk factors for the development of respiratory worsening and the possible association with complications.

02

Conditions studied

  • Blood Transfusion Complication
  • Blood Transfusion Associated Adverse Reactions
  • Respiratory Complication
  • Respiratory Morbidity

Browse trials for

03

In context

Transfusion Reaction

56 studies on the registry are indexed under Transfusion Reaction; 12 are open to participants now.

This study's planned enrollment of 71 is close to the median of 71 across 23 interventional studies indexed under Transfusion Reaction.

Browse Transfusion Reaction studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 1 Month
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • admitted newborns requiring blood transfusions as per local practice and/or international guidelines

Exclusion criteria

Exclusion Criteria:

  • newborns with major malformations
  • need for palliative care
  • lack of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (estimated)

Study arms

  • Other
    study group

    All infants undergoing blood transfusions will be enrolled in the study

    Diagnostic Test: lung ultrasound

Interventions

  • Diagnostic testlung ultrasound

    Lung ultrasound examinations will be performed within 6 hours before and after blood transfusion to assess interstitial-alveolar fluid retention and calculate a LUS score

06

What researchers measure

Primary outcomes

  1. Changes in lung ultrasound score (LUS score) before and after transfusions

    LUS score according to previous publications (Brat et al., 2015) will be calculated

    Time frame: within 6 hours before and after the transfusion

  2. Changes in non-invasive peripheral oxygen saturation/fraction of inspired oxygen (SFR) before and after transfusions

    non-invasive peripheral oxygen saturation/fraction of inspired oxygen (SFR) will be calculated from clinical charts: data validated by caregivers (primary nurses) will be extracted from the electronic charts to calculate this ratio

    Time frame: within 6 hours before and after the transfusion

Secondary outcomes

  1. Changes in ventilatory parameters (mean airway pressure) for patients on nasal continuous positive airway pressure (nCPAP) or mechanical ventilation

    MAP as displayed by ventilators will be recorded as median values

    Time frame: within 6 hours before and after the transfusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2025, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 5, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jan 15, 2026
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06443515
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Jul 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Jan 15, 2026 (estimated)
Last update
Sep 24, 2024

Study contacts

Stefano Nobile, MD, PhD, MSc
Contact
stefano.nobile@policlinicogemelli.it
+39 06 30151
Stefano Nobile, MD, PhD, MSc
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion